title: CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.
authors.forename: Jana
authors.initials: J
authors.lastname: Moravcová
authors.forename: Jana
authors.initials: J
authors.lastname: Rulcová
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Polák
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Zemanová
authors.forename: Hana
authors.initials: H
authors.lastname: Klamová
authors.forename: Cedrik
authors.initials: C
authors.lastname: Haskovec
mesh_terms: D000328:Adult; D001549:Benzamides; D020732:Cytogenetic Analysis / Q000379:methods; D005091:Exons; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D014644:Genetic Variation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl